hepatocellular carcinoma
FDA Approves Opdivo With Yervoy for Unresectable or Metastatic Hepatocellular Carcinoma
The FDA has approved Opdivo with Yervoy for the first-line treatment of adult patients with unresectable or ...
APRIL 14, 2025
FDA Approves Opdivo Qvantig for Subcutaneous Injection
The FDA approved nivolumab plus hyaluronidase-nvhy (Opdivo Qvantig, Bristol Myers Squibb) for subcutaneous ...
DECEMBER 30, 2024
FDA Approves Tecentriq Hybreza for Subcutaneous Injection for All Adult Indications of IV Tecentriq
The FDA has approved Tecentriq Hybreza for subcutaneous injection as the intravenous formulation of Tecentriq.
SEPTEMBER 16, 2024
Researchers Question Value of 30-Day Readmission Metric in HCC
Researchers at several centers across the country are raising doubts about rates of 30-day readmission after liver ...
FEBRUARY 22, 2022
BMS Withdraws Opdivo Indication for HCC Monotherapy
In consultation with the FDA, Bristol Myers Squibb (BMS) has voluntarily withdrawn from the U.S. market the ...
JULY 27, 2021
Nivolumab-Ipilimumab Combo Approved to Treat Previously Treated HCC
The FDA granted accelerated approval for the use of nivolumab plus ipilimumab to treat hepatocellular carcinoma in ...
MARCH 12, 2020
FDA Grants Cabometyx New Indication for HCC
New treatment indicated for most common cause of liver cancer.
JANUARY 16, 2019
Keytruda Granted Accelerated Approval for Treatment of HCC
The FDA expanded the approved indications for pembrolizumab (Keytruda, Merck), granting the checkpoint inhibitor ...
NOVEMBER 16, 2018
FDA Approves New Indication for Lenvima for HCC
The FDA approved a new indication for Lenvima for first-line treatment of patients with unresectable hepatocellular ...
AUGUST 17, 2018
Large Study Confirms DAAs Protect Against HCC When SVR Achieved
Patients with hepatitis C who are successfully treated with direct-acting antiviral agents experience a dramatic ...
MARCH 1, 2018
FDA Grants Opdivo New Indication for HCC Patients Previously Treated With Sorafenib
The U.S. burden of hepatocellular carcinoma is significant. A recent ACS report noted that death rates from liver ...
OCTOBER 2, 2017